It can also help regulate your blood sugar levels and improve insulin sensitivity, which can benefit people with obesity-related conditions such as type 2 diabetes
The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)
All AbMole products are for research use only, cannot be used for human consumption or veterinary use
Highlights of Prescribing Information for Wegovy
Manufacturer savings programs reduce expenses to $25 monthly for eligible patients
Uninsured patients receive options to ensure treatment remains attainable